Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Brigitte Michelsen; Mikkel Østergaard; Michael John Nissen; Adrian Ciurea; Burkhard Möller; Lykke Midtbøll Ørnbjerg; Jakub Zavada; Bente Glintborg; Alan MacDonald; Karin Laas; Dan Nordström; Bjorn Gudbjornsson; Florenzo Iannone; Pasoon Hellmand; Tore Kristian Kvien; Ana Maria Rodrigues; Catalin Codreanu; Ziga Rotar; Isabel Castrejón Fernández; Johan Karlsson Wallman; Jiri Vencovsky; Anne Gitte Loft; Maureen Heddle; Sigrid Vorobjov; Anna-Mari Hokkanen; Gerdur Gröndal; Marco Sebastiani; Marleen van de Sande; Eirik Klami Kristianslund; Maria José Santos; Corina Mogosan; Matija Tomsic; Federico Díaz-González; Daniela di Giuseppe; Merete Lund Hetland

doi:10.1016/j.lanepe.2023.100706

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Brigitte Michelsen^*
, Mikkel Østergaard
, Michael John Nissen
, Adrian Ciurea
, Burkhard Möller
, Lykke Midtbøll Ørnbjerg
, Jakub Zavada
, Bente Glintborg
, Alan MacDonald
, Karin Laas
, Dan Nordström
, Bjorn Gudbjornsson
, Florenzo Iannone
, Pasoon Hellmand
, Tore Kristian Kvien
, Ana Maria Rodrigues
, Catalin Codreanu
, Ziga Rotar
, Isabel Castrejón Fernández
, Johan Karlsson Wallman

Jiri Vencovsky, Anne Gitte Loft, Maureen Heddle, Sigrid Vorobjov, Anna-Mari Hokkanen, Gerdur Gröndal, Marco Sebastiani, Marleen van de Sande, Eirik Klami Kristianslund, Maria José Santos, Corina Mogosan, Matija Tomsic, Federico Díaz-González, Daniela di Giuseppe, Merete Lund Hetland

^*Corresponding author for this work

Affiliatie UvA

University of Copenhagen
Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
Research Unit, Sørlandet Hospital, Kristiansand, Norway
University of Geneva
University Hospital Zürich
University of Bern
Institute of rheumatology
Charles University
NHS Grampian
East-Tallinn Central Hospital
Helsinki University Hospital
Landspitali University Hospital
University of Iceland
University of Bari
Amsterdam UMC - University of Amsterdam
Sociedade Portuguesa de Reumatologia
NOVA University Lisbon
Hospital dos Lusíadas
Carol Davila University of Medicine and Pharmacy
University of Ljubljana
Hospital General Universitario Gregorio Marañon
Complutense University
Lund University
Aarhus University
University of Aberdeen
National Institute for Health Development
University of Modena and Reggio Emilia
Department of Rheumatology, Amsterdam Rheumatology Immunology Center (ARC), Amsterdam, The Netherlands
Hospital Garcia de Orta
University of Lisbon
University of La Laguna
Hospital Universitario de Canarias
Karolinska Institutet

Research output: Contribution to journal › Review article › Academic › peer-review

21 Downloads (Pure)

Abstract

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

Original language	English
Article number	100706
Journal	The Lancet Regional Health - Europe
Volume	33
DOIs	https://doi.org/10.1016/j.lanepe.2023.100706
Publication status	Published - 1 Oct 2023

Keywords

Axial spondyloarthritis
Health policy
Psoriatic arthritis
Treatment recommendations

Access to Document

10.1016/j.lanepe.2023.100706

Differences-and-similarities-between-the-eularasas-eular-and-national-recommendations-for-treatment-of-patients-with-ps.pdfFinal published version, 1.03 MBLicence: CC BY

Cite this

Michelsen, B., Østergaard, M., Nissen, M. J., Ciurea, A., Möller, B., Ørnbjerg, L. M., Zavada, J., Glintborg, B., MacDonald, A., Laas, K., Nordström, D., Gudbjornsson, B., Iannone, F., Hellmand, P., Kvien, T. K., Rodrigues, A. M., Codreanu, C., Rotar, Z., Castrejón Fernández, I., ... Hetland, M. L. (2023). Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe. The Lancet Regional Health - Europe, 33, Article 100706. https://doi.org/10.1016/j.lanepe.2023.100706

@article{23da8e42df644b789e9c026fa83f3f1d,

title = "Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe",

abstract = "This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.",

keywords = "Axial spondyloarthritis, Health policy, Psoriatic arthritis, Treatment recommendations",

author = "Brigitte Michelsen and Mikkel {\O}stergaard and Nissen, \{Michael John\} and Adrian Ciurea and Burkhard M{\"o}ller and {\O}rnbjerg, \{Lykke Midtb{\o}ll\} and Jakub Zavada and Bente Glintborg and Alan MacDonald and Karin Laas and Dan Nordstr{\"o}m and Bjorn Gudbjornsson and Florenzo Iannone and Pasoon Hellmand and Kvien, \{Tore Kristian\} and Rodrigues, \{Ana Maria\} and Catalin Codreanu and Ziga Rotar and \{Castrej{\'o}n Fern{\'a}ndez\}, Isabel and Wallman, \{Johan Karlsson\} and Jiri Vencovsky and Loft, \{Anne Gitte\} and Maureen Heddle and Sigrid Vorobjov and Anna-Mari Hokkanen and Gerdur Gr{\"o}ndal and Marco Sebastiani and \{van de Sande\}, Marleen and Kristianslund, \{Eirik Klami\} and Santos, \{Maria Jos{\'e}\} and Corina Mogosan and Matija Tomsic and Federico D{\'i}az-Gonz{\'a}lez and \{di Giuseppe\}, Daniela and Hetland, \{Merete Lund\}",

note = "Funding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG . Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = oct,

day = "1",

doi = "10.1016/j.lanepe.2023.100706",

language = "English",

volume = "33",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

publisher = "Elsevier Ltd",

}

Michelsen, B, Østergaard, M, Nissen, MJ, Ciurea, A, Möller, B, Ørnbjerg, LM, Zavada, J, Glintborg, B, MacDonald, A, Laas, K, Nordström, D, Gudbjornsson, B, Iannone, F, Hellmand, P, Kvien, TK, Rodrigues, AM, Codreanu, C, Rotar, Z, Castrejón Fernández, I, Wallman, JK, Vencovsky, J, Loft, AG, Heddle, M, Vorobjov, S, Hokkanen, A-M, Gröndal, G, Sebastiani, M, van de Sande, M, Kristianslund, EK, Santos, MJ, Mogosan, C, Tomsic, M, Díaz-González, F, di Giuseppe, D & Hetland, ML 2023, 'Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe', The Lancet Regional Health - Europe, vol. 33, 100706. https://doi.org/10.1016/j.lanepe.2023.100706

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe. / Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John et al.
In: The Lancet Regional Health - Europe, Vol. 33, 100706, 01.10.2023.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

AU - Michelsen, Brigitte

AU - Østergaard, Mikkel

AU - Nissen, Michael John

AU - Ciurea, Adrian

AU - Möller, Burkhard

AU - Ørnbjerg, Lykke Midtbøll

AU - Zavada, Jakub

AU - Glintborg, Bente

AU - MacDonald, Alan

AU - Laas, Karin

AU - Nordström, Dan

AU - Gudbjornsson, Bjorn

AU - Iannone, Florenzo

AU - Hellmand, Pasoon

AU - Kvien, Tore Kristian

AU - Rodrigues, Ana Maria

AU - Codreanu, Catalin

AU - Rotar, Ziga

AU - Castrejón Fernández, Isabel

AU - Wallman, Johan Karlsson

AU - Vencovsky, Jiri

AU - Loft, Anne Gitte

AU - Heddle, Maureen

AU - Vorobjov, Sigrid

AU - Hokkanen, Anna-Mari

AU - Gröndal, Gerdur

AU - Sebastiani, Marco

AU - van de Sande, Marleen

AU - Kristianslund, Eirik Klami

AU - Santos, Maria José

AU - Mogosan, Corina

AU - Tomsic, Matija

AU - Díaz-González, Federico

AU - di Giuseppe, Daniela

AU - Hetland, Merete Lund

N1 - Funding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG . Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2023 The Author(s)

PY - 2023/10/1

Y1 - 2023/10/1

N2 - This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

AB - This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

KW - Axial spondyloarthritis

KW - Health policy

KW - Psoriatic arthritis

KW - Treatment recommendations

UR - https://www.scopus.com/pages/publications/85166759844

U2 - 10.1016/j.lanepe.2023.100706

DO - 10.1016/j.lanepe.2023.100706

M3 - Review article

C2 - 37601339

SN - 2666-7762

VL - 33

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

M1 - 100706

ER -

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this